Global pathogen reduction Cerus has a globally available INTERCEPT system for platelets and plasma with CE and FDA approvals, indicating strong international adoption and potential for cross-selling additional pathogen-reduced components or expanded use in transfusion safety programs.

U.S. fibrinogen opportunity The INTERCEPT Fibrinogen Complex is approved in the US for pathogen-reduced cryoprecipitated fibrinogen, presenting a clear upsell path to hospitals and blood centers seeking safer, ready-to-use hemostatic products for bleeding and massive hemorrhage management.

North America momentum Q2 2026 results show solid product revenue growth and raised full-year guidance, signaling expanding customer adoption in North America and a foundation for expanding international deployment of INTERCEPT systems.

Cost efficiency focus Management’s emphasis on reducing research costs while leveraging government funding suggests a favorable trend for profitability; sales teams can highlight cost-per-unit reductions and long-term value of safer blood components to payers and health systems.

Portfolio expansion potential Late-stage development of the INTERCEPT red blood cell system and ongoing product breadth position Cerus to target blood centers, hospitals, and trauma centers with a comprehensive safety-enhanced portfolio, creating cross-sell opportunities across components and countries.